

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Chronic lymphocytic leukemia transformation into high-grade lymphoma: a description of Richter's syndrome in eight dogs

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1529537> since 2022-01-28T12:40:05Z

Published version:

DOI:10.1111/vco.12172

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



**CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION
INTO HIGH GRADE LYMPHOMA: A DESCRIPTION OF
RICHTER SYNDROME IN 8 DOGS**

Journal:	<i>Veterinary and Comparative Oncology</i>
Manuscript ID:	Draft
Manuscript Type:	Original Article
Keywords:	Clinical Pathology, Hematology, Oncology, Small Animal, Pathology, Comparative Oncology

SCHOLARONE™
Manuscripts
Review Only

**CHRONIC LYMPHOCYTIC LEUKEMIA TRANSFORMATION INTO HIGH GRADE
LYMPHOMA: A DESCRIPTION OF RICHTER SYNDROME IN 8 DOGS**

Comazzi, S^a, Martini V^a, Riondato F^b, Poggi A^b, Stefanello D^a, Marconato L^c, Albonico F^a, Gelain
ME^d

^a Dipartimento di Scienze Veterinarie e Sanità Pubblica, Università degli Studi di Milano, Italy

^b Dipartimento di Scienze Veterinarie, Università degli Studi di Torino, Italy

^c Centro Oncologico Veterinario, Sasso Marconi, BO, Italy

^d Dipartimento di Biomedicina Comparata e Alimentazione, Università degli Studi di Padova, Italy

Running title: Richter syndrome in 8 dogs

ABSTRACT

Richter's syndrome (RS) is the rapid development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia (CLL). In humans, RS occurs in 2-20% of CLL and frequently transforms into diffuse large B-cell lymphoma but reports in veterinary medicine are scarce.

This study retrospectively describes 8 dogs with CLL progressing into RS.

From a total of 153 dogs with CLL (93 T CD8+ and 55 B-CLL) RS was demonstrated in 8 cases (5.2%); 2 with T-cell (2.2%) and 6 with a B-cell immunophenotype (10.9%).

When RS occurred, lymphocyte counts were decreased compared to CLL. Mild anaemia was found in 5 dogs and thrombocytopenia in 2 dogs. Clinical signs were frequent and included lymph node swelling, coughing, vomiting, neurological signs and poor clinical conditions. Independently from the therapy, RS was associated with a short survival (median 62 days).

Richter syndrome should be considered as a possible unfavourable evolution in canine CLL.

Keywords: dog, chronic lymphocytic leukaemia, Richter syndrome, high grade lymphoma, transformation, flow cytometry

INTRODUCTION

Chronic lymphocytic leukaemia (CLL) in people is the most common haematological malignancy in western countries and its associations with second lymphoid and non-lymphoid neoplasms is well documented.¹ Richter's transformation or Richter's syndrome- (RS) is a clinico-pathological term used to describe the rapid development of an aggressive lymphoma in patients with CLL. In humans, RS occurs in 2-20% of CLL cases and most frequently (90%) CLL transforms into diffuse large B-cell lymphoma (DLBCL) while more rarely (10%) into Hodgkin lymphoma.² In contrast the transformation into large T-cell lymphoma in T-CLL patients has been rarely described.^{3,4} In the pathogenesis of RS the large cells observed may arise from a transformation of the original CLL clone in approximately 80% of cases, due to the accumulation of genetic and/or epigenetic lesions.⁵ In the remaining 20% of cases, RS represents a new neoplasm in which the pathogenetic mechanism is more likely related to host genetic background or microenvironmental dysfunction, enhancing the probability of DLBCL. CLL is a common haematological disorder in dogs of middle-elderly age, showing an indolent course. Late in the course of disease, dogs with CLL typically experience progressive disease, multiorgan dysfunction, or blastic transformation in acute leukemia.⁶ To our knowledge, only two cases of canine RS have been previously documented.⁷ Recently, the simultaneous presence of T-CLL and DLBCL has been reported in one dog with no evidence of progression from one disease to the other.⁸ Aim of this study was to retrospectively describe 8 cases of CLL in dogs progressing into RS. The clinical and clinico-pathological presentation is compared with the analogous human counterpart.

MATERIAL AND METHODS

The databases of the flow cytometry service of the University of Milan and Turin were interrogated for cases of possible RS. CLL was classified as previously described⁹ whereas the diagnosis of RS

was defined based on the following aspects: 1) documented history of CLL; 2) development of systemic lymphadenopathy being suggestive of high grade lymphoma based on cytology, immunophenotype and, if possible, histopathology

Samples were submitted by veterinarians and referral laboratories and shipped within 24 hours from collection. Flow cytometric immunophenotyping was performed as previously described on peripheral blood and bone marrow for the diagnosis of CLL⁹, and on lymph node aspirates¹⁰ for the diagnosis of RS.

For each case, the referring veterinarians were contacted and asked for a complete follow-up, including serial CBCs, treatment (if any), survival and cause of death. For 2 cases (case 1 and 3), DNA samples obtained from peripheral blood at the time of CLL diagnosis and later during transformation into RS were available. On these samples, PARR (PCR for Antigen Receptor Rearrangements) analysis was performed according to Burnett et al.¹¹ in order to verify whether RS might be considered as an evolution of the pre-existing leukaemia rather than a second malignancy. Results were not analysed statistically due to the low number of cases and the extreme heterogeneity of the data.

RESULTS

Between January 2006 and December 2014, a total of 2443 cases (either peripheral blood, bone marrow or lymph node aspirates) were received for flow cytometric immunophenotyping of neoplastic diseases at the two units. A total of 153 cases were diagnosed as CLL, 93 of which having T CD8+ immunophenotype (60,8%) and 55 having a B immunophenotype (35,9%).

Different atypical phenotypes were identified in the remaining 5 cases (3.3%). RS was demonstrated in 8 cases (5.2%): 2 having a T-cell immunophenotype (2.2%) and 6 having a B-cell immunophenotype (10.9%).

Signalment and hematologic data of the 8 cases are summarized in Table 1.

Collection of clinical data, when available, confirmed the presence of only minor symptoms at diagnosis of CLL, whereas clinical signs detected during RS were frequent and variable, including coughing, vomiting, neurological signs and poor clinical conditions.

Regarding CBC, at the time of CLL diagnosis all dogs showed lymphocytosis, ranging from 27,000 to > 100,000 lymphocyte/mm³, 1 dog presented with a slight anaemia, 1 had thrombocytopenia and one had thrombocytosis.

When RS occurred, the overall lymphocyte counts were decreased in all cases. In particular, in 4 out of 8 cases, lymphocytosis was still present, and in 2 cases leukopenia with lymphopenia was observed. At this time, mild anemia was detectable in 5 dogs and thrombocytopenia in 2 dogs. A double population of small lymphocytes and large blasts was clearly identifiable in peripheral blood and/or bone marrow in 6 cases (figure 1).

Cytology of enlarged lymph node confirmed the presence of large cell high grade lymphoma. Flow cytometry confirmed a decrease of small lymphocyte in peripheral blood, and the presence of a prevalent population of large neoplastic cells indistinguishable from those of a primary large high grade lymphoma in the lymph node (Figure 2).

Treatment and follow-up are summarized in table 2. Five CLL cases were treated with chlorambucil and prednisone, whereas no treatment was pursued in 3 dogs. When RS occurred, a CHOP-based chemotherapy regimen was administered in 4 dogs, while 2 dogs still received the previous therapy (chlorambucil + prednisone). In 2 cases the owners elected euthanasia.

Independently from the duration of CLL phase, RS was associated with a short survival time (range, 1 to 83 days, median 62 days).

PARR was tested only in two samples one with T cell CLL/RS and one with B cell CLL/RS (Table 1, no 1 and 3 respectively) (Figure 3). In both cases, a similar antigen receptor rearrangement was found with PCR products at the same molecular weight.

DISCUSSION

RS is a clinical condition in which indolent CLL evolves into a more aggressive high-grade lymphoma. The present study describes clinical and clinico-pathological features of a series of 8 dogs presenting with CLL, eventually evolving into RS.

In human CLL patients, RS transformation is characterized by the rapid onset of systemic symptoms with sudden clinical deterioration, lymphadenomegaly, hepatomegaly and/or splenomegaly. Frequently, the neoplastic population arises from lymph nodes or bone marrow eventually spreading to other organs. Less commonly, RS involves extranodal sites such as gastrointestinal tract, central nervous system, skin, lungs or kidneys¹². Occasionally, circulating blast cells may be present together with anemia, neutropenia and thrombocytopenia, which can be also related to the underlying CLL. The final diagnosis of RS requires a lymph node biopsy and the morphological identification of large lymphoma cells, thereby allowing the distinction from CLL progression or CLL refractory to therapy¹³. In some cases, small lymphocytes from CLL and large blasts from DLBCL may coexist as a composite lymphoma, while less frequently some patients may develop Hodgkin disease¹⁴. In very few cases, a T-cell lymphoma may arise from a T-CLL³ or B-CLL patients may develop a high grade T-cell lymphoma¹⁵.

To the authors' knowledge, RS in dogs has been previously described only in 2 cases out of a series of 22 CLL, but no data on phenotype, follow up and evolution of the solid lesions were reported⁷.

In the present study, 6 cases of RS of B phenotype are described. They represent more than 10% of the total number of B-CLL included in our records. This percentage is similar to what reported in human medicine, as in the B-CLL population, the prevalence of RS development ranges from 2-to 20%,^{2,16}. On the contrary, in our records only 2 cases of T-CLL, which is the most common CLL subtype in dogs, experienced RS transformation. Although the number of cases is too low to define a precise prevalence, these data confirm that RS should be considered as a possible evolution of CLL also in dogs. In both species (humans and dogs), RS occurs more often in B-CLL than T-CLL cases, although T-CLL is by far less common than B-CLL in humans, thus possibly biasing the comparative aspects. In humans the prognosis of RS transformation is generally poor. However, the

1
2
3 pattern of survival is not homogeneous and may be predicted by some prognostic factors by which
4
5 phenotype, with RS developing from T-CLL possibly harbouring a better outcome.¹⁴ The reason for
6
7 this different behaviour, both in the prevalence of RS evolution and in the response to therapies, is
8
9 still unknown.

10
11 Hematologic and clinical features of CLL undergoing RS are not different to those previously
12
13 reported in dogs with CLL.¹⁷ Severe cytopenias are uncommon and only minimal anaemia and
14
15 thrombocytopenia may occur.

16
17 From the present study emerges that clinically, patients with Richter transformation show an
18
19 aggressive disease course, with rapidly enlarging lymph nodes and hepato-splenomegaly.
20
21 Interestingly, Richter transformation occurred in concomitance with a decrease of lymphocyte
22
23 number in all cases and with a decrease of erythrocytes leading to a mild anaemia in most cases.
24
25 Lymphocyte count in some cases may return within reference intervals or even fall below lower
26
27 reference limit. This suggests that clinicians should carefully interpret a rapid decrease of
28
29 lymphocyte number and the onset of anaemia in dogs with CLL as a possible sign of evolution
30
31 towards a more aggressive phase.
32
33

34
35 In agreement with the human literature¹⁴, prognosis was poor in dogs as well, with a median
36
37 survival of 41 days. Notably, response to treatment was scarce and no remotely comparable to the
38
39 response commonly obtained in primarily occurring high grade lymphomas.^{18,19}

40
41 The majority of human RS cases are clonally related to the original CLL clone, and only rarely they
42
43 represent a high grade lymphoma developing de novo likely due to immunologic derangements or
44
45 genetic background of the CLL host.^{2,14}

46
47 To our knowledge, to date no similar molecular biology studies have been performed in dogs. In the
48
49 present study, we succeeded in recovering frozen DNA from a couple of cases in which samples
50
51 from blood in the CLL phase and aspirates from lymph node in RS had been harvested in our tissue
52
53 bank. PARR showed an identical B-cell receptor rearrangement in CLL and RS phase, thus
54
55 suggesting that they represent an evolution of the same disease. Unfortunately, PARR was not
56
57
58
59
60

carried out in most cases. We can't completely rule out that, similarly to human medicine, some cases develop a second malignancy. This may be true particularly for case #2, in which a double negative CD4-CD8- high-grade lymphoma developed from a primary CD8+ CLL.

The main limit of the present study is the low number of cases due to the low prevalence of both B-CLL and RS in the canine population. In addition, data were retrospectively collected from the database of the flow cytometry service of the two units: thus, prevalence of RS transformation might have been underestimated in the present study, since it is possible that owners or referring veterinarians did not repeat sampling and immunophenotyping at time of transformation, particularly because of the disregarded nature of RS in veterinary medicine. The real percentage of CLL undergoing RS should be better evaluated by a prospective study.

Another pitfall is the lack of a complete follow-up in some cases as well as a lack of a standardized therapeutic approach, which are inherent to the retrospective nature of the study.

Finally, it would be interesting to confirm the data on PARR with a higher number of cases in which DNA from the CLL phase and during SR are available.

In conclusion, our findings suggests that RS may be considered a possible transformation of CLL, mainly of B-phenotype, also in dogs. Similarly to human medicine, RS is linked to the onset of clinical signs and lymphadenomegaly with a cytological aspects of a high grade large cell lymphoma. During RS, lymphocyte counts generally decrease and anemia may occur. Prognosis is generally poor with a scarce response to chemotherapy. Further studies on the possible predisposing factors to RS are needed.

Acknowledgement

The authors wish to thank Dr Angelo Capasso and the referring clinicians for providing follow-up data.

REFERENCES

1. Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. *MedGenMed*. 2007;9(4):35.

2. Jamroziak K1, Tadmor T, Robak T, Polliack A. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. *Leuk Lymphoma*. 2015 21:1-10.

3. Matutes E, Wotherspoon AC, Parker NE, Osuji N, Isaacson PG, Catovsky D. Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma. *Br J Haematol*. 2001;115(4):801-6.

4. Nowell P, Finan J, Glover D, Guerry D. Cytogenetic evidence for the clonal nature of Richter's syndrome. *Blood*. 1981;58(1):183-6.

5. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspective. *Hematol Oncol*. 2009;27(1):1-10.2009.

6. Workman HC, Vernau W. Chronic lymphocytic leukemia in dogs and cats: the veterinary perspective. *Vet Clin North Am Small Anim Pract*. 2003;33(6):1379-99, viii.

7. Leifer CE, Matus RE Chronic lymphocytic leukemia in the dog: 22 cases (1974-1984). *J Am Vet Med Assoc*. 1986 Jul 15;189(2)

8. Okawa T, Hiraoka H, Wada Y, Baba K, Itamoto K, Mizuno T, et al. Development of high-grade B-cell lymphoma concurrent with T-cell chronic lymphocytic leukemia in a dog. *J Vet Med Sci*. 2012 May;74(5):677-80.

9. Comazzi S, Gelain ME, Martini V, Riondato F, Miniscalco B, Marconato L, et al. Immunophenotype predicts survival time in dogs with chronic lymphocytic leukemia. *J Vet Intern Med*. 2011;25(1):100-6.

10. Gelain ME, Mazzilli M, Riondato F, Marconato L, Comazzi S. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. *Vet Immunol Immunopathol*. 2008 15;121(3-4):179-88

- 1
2
3 11. Burnett RC, Vernau W, Modiano JF, Olver CS, Moore PF, Avery AC. Diagnosis of canine
4 lymphoid neoplasia using clonal rearrangements of antigen receptor genes. *Vet Pathol.*
5 2003;40(1):32-41
6
7
8
- 9 12. Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other
10 manifestations. *Br J Haematol.* 2008;142(5):709-16.
11
12
- 13 13. Eichhorst B1, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic
14 lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and
15 follow-up *Ann Oncol.* 2008;19 Suppl 2:ii60-2.
16
17
18
- 19 14. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic
20 strategies.
21 *Cancer.* 2005 15;103(2):216-28..
22
23
24
- 25 15. Martinez A, Pittaluga S, Villamor N, Colomer D, Rozman M, Raffeld M, et al. Clonal T-cell
26 populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients:
27 clinicopathologic observations and molecular analysis. *Am J Surg Pathol.* 2004;28(7):849-
28 58.
29
30
31
32
33
34
35
- 36 16. Rossi D, Gaidano G. Richter syndrome. *Adv Exp Med Biol.* 2013;792:173-91
37
- 38 17. Tasca S, Carli E, Caldin M, Menegazzo L, Furlanello T, Gallego LS. . Hematologic
39 abnormalities and flow cytometric immunophenotyping results in dogs with hematopoietic
40 neoplasia: 210 cases (2002-2006). *Vet Clin Pathol.* 2009;38(1):2-12
41
42
43
44
- 45 18. Aresu L, Martini V, Rossi F, Vignoli M, Sampaolo M, Aricò A, et al. Canine indolent and
46 aggressive lymphoma: clinical spectrum with histologic correlation. *Vet Comp Oncol.* 2013
47 Jun 20. doi: 10.1111/vco.12048.
48
49
50
- 51 19. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, et al.
52 Prognostic significance of morphological subtypes in canine malignant lymphomas during
53 chemotherapy. *Vet J.* 2004;167(2):158-66
54
55
56
57
58
59
60

Table 1

No	breed	gender	age	lymph/mmcll	CBC CLL	phenotype CLL	lymph/mmcll RS	CBC RS	phenotype RS
1	golden retriever	f	9 y	75,600	no alterations	T CD8+	49,938	anemia (Ht 30), circulating blasts	T CD8+
2	carlino	fs	13 y	27,790	anemia (HT 20)	T CD8+	430	anemia (HT 24), circulating blasts	T CD4-CD8-
3	boxer	f	10 y	27,000	no alterations	B	400	no alterations	B
4	WHWT	fs	9 y	48,450	no alterations	B	1,300	anemia (HT 26), circulating blasts	B
5	mongrel	m	16 y	28,500	thrombocytosis	B	7,230	anemia (HT 30), circulating blasts	B
6	English setter	m	13 y	>100,000	no alterations	B	29,230	anemia (HT 25), thrombocytopenia circulating blasts	B
7	beagle	fs	8 y	110,000	thrombocytopenia	B	4,280	no alterations	B
8	dobermann	fs	8 y	29,485	no alterations	B	11,570	thrombocytopenia circulating blasts	B

Table 2

No	therapy for CLL	time to progression	therapy for RS	cause of death	survival with RS	overall survival
1	chlorambucile + prednisone	210 d	Wisconsin Madison + cytosine	high grade lymphoma, progressive disease	60 d	270 d
2	no therapy	303 d	no therapy (euthanasia)	euthanasia	1 d	304 d
3	no therapy	488 d	CHOP	high grade lymphoma progressive disease + hepatic adenocarcinoma	83 d	571 d
4	chlorambucile + prednisone;	89 d	CHOP	high grade lymphoma, progressive disease + renal failure	24 d	113 d
5	no therapy	250 d	COP	high grade lymphoma, progressive disease + renal failure	14 d	264 d
6	chlorambucile + prednisone;	112 d	no therapy (euthanasia)	euthanasia	1 d	113 d
7	chlorambucile + prednisone;	266 d	chlorambucile + prednisone + lomustine	high grade lymphoma progressive disease, euthanasia	58 d	324 d
8	chlorambucile + prednisone	63 d	chlorambucile + prednisone	high grade lymphoma progressive disease, euthanasia	62 d	125 d




Figure 1: bone marrow slide from case no. 6. Large blast cells (black arrows) are identifiable together with many small lymphocytes (red arrows). May Grünwald-Giemsa stain, 100x 295x221mm (300 x 300 DPI)




Figure 2: Flow cytometric scattergrams of peripheral blood (A,B,C,D) and lymph node (E,F) from dog no.3. At time of diagnosis of CLL (A,B) an abundant population of small B lymphocytes was found. During Richter transformation B lymphocytes decreased in peripheral blood (C,D) and large B lymphoid blast cells appeared in the lymph node aspirate (E,F)

147x190mm (300 x 300 DPI)




Figure 3: PARR for BCR (A) and TCR (B) on dog #3 and #1 with B and T CLL/RS respectively. Clonal bands at the same molecular weight were detected on blood in CLL phase and in lymph node in RS. Samples were run in duplicate.
232x118mm (300 x 300 DPI)

Legends for illustrations

Table 1: signalment, hematologic and immunophenotypic features of 8 dogs with chronic lymphocytic leukemia undergoing Richter transformation.

Table 2: therapy and follow up data of 8 dogs with chronic lymphocytic leukemia undergoing Richter transformation.

Figure 1: bone marrow slide from case no. 6. Large blast cells (black arrows) are identifiable together with many small lymphocytes (red arrows). May Grünwald-Giemsa stain, 100x

Figure 2: Flow cytometric scattergrams of peripheral blood (A,B,C,D) and lymph node (E,F) from dog no.3. At time of diagnosis of CLL (A,B) an abundant population of small B lymphocytes was found. During Richter transformation B lymphocytes decreased in peripheral blood (C,D) and large B lymphoid blast cells appeared in the lymph node aspirate (E,F)

Figure 3: PARR for BCR (A) and TCR (B) on dog #3 and #1 with B and T CLL/RS respectively. Clonal bands at the same molecular weight were detected on blood in CLL phase and in lymph node in RS. Samples were run in duplicate.